The validity of this concept has first been demonstrated by the therapeutic efficacy of the BTK inhibitor ibrutinib in ABC DLBCL and other lymphoid cancers relying on chronic BCR signaling [67,89,253,254]. Here, BCR is linked to diffuse large B-cell lymphoma.